Teixobactin Development for Anthrax
Teixobactin Development for Anthrax
批准号:
10078521
负责人:
Dallas Hughes
金额:
$100.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-15 至 2023-05-31
关键词:
AcuteAnimal ModelAnimalsAnthrax diseaseAntibiotic TherapyAntibioticsBacillus anthracisBindingBinding ProteinsBioreactorsCell CountCell WallCellsClinicalClinical ResearchClinical TrialsContractsCyclic GMPDevelopmentDoseDrug KineticsDrug resistanceDrug usageEngineeringEvaluationExposure toFermentationFundingFutureGoalsGram-Positive BacteriaGrantHistopathologyHumanIn VitroInfectionInhalationLengthLipid IIILipidsLungManufacturer NameMedicalMethodsModelingMonkeysMycobacterium tuberculosisOnset of illnessOrganOryctolagus cuniculusPathogenicityPeptidoglycanPharmaceutical PreparationsPhasePhase I Clinical TrialsPlasmaPlasma ProteinsPneumococcal InfectionsPreparationProductionProgram DevelopmentPropertyProteinsResistanceResistance developmentRunningSafetySamplingSepticemiaSerumSkinSourceStaphylococcus aureusStructureTeichoic AcidsTestingTexasTherapeuticTissuesToxicologyUniversitiesWorkanimal efficacyanimal rulebiothreatcombatdrug resistant pathogenefficacy studymethicillin resistant Staphylococcus aureusmicrobialmutantnonhuman primatepathogenpreclinical developmentresistance frequencyscale upside effecttherapy developmenttherapy resistantweapons
中文摘要
摘要
该项目的目标是继续开发 teixobactin (TXB) 作为抗生素
对抗武器化的炭疽病。这项工作将与正在进行的临床前试验同时进行
开发计划,该计划正在推进 TXB 治疗其他严重感染引起的感染
病原体,例如耐甲氧西林金黄色葡萄球菌 (MRSA)。 TXB已显示
在多种动物感染模型(包括兔子吸入模型)中具有出色的疗效
炭疽病最近在德克萨斯大学医学分部(德克萨斯州加尔维斯顿)进行。由于 TXB
不寻常的作用机制——结合两个不同的细菌细胞壁目标,这两个目标都不是
蛋白质 – TXB 代表了一种特别没有耐药性的化合物的例子
发展,因此是炭疽病对策的优秀候选者。
这笔赠款的工作将包括以下具体目标: 目标 1 将至少提供
50 克非 cGMP teixobactin 来完成提案中的所有研究。此外,至少有200
克 cGMP 材料将由合同制造商生产,用于计划的未来研究。
目标 2 将重点开展以下研究,以进一步了解 TXB 的体外特性: (a) MIC
针对一组关键炭疽芽孢杆菌分离株进行测试,包括对当前炭疽杆菌具有抗性的分离株
毒品; (b)确定炭疽芽孢杆菌对替克巴汀的耐药频率; (c) 蛋白质结合
使用兔子、非人灵长类动物 (NHP) 和人血清来测定游离药物水平的研究。
目标 3 将确定兔炭疽疗效模型中的最小治疗 TXB 剂量,其中
相关的药代动力学(PK)分析和组织病理学。目标 3 中的信息
除了与该项目同时进行的毒理学、安全性和 PK/PD 研究之外,还将有助于
告知 NHP 和人体剂量。
在本次拨款结束时,TXB 将准备进入符合 GLP 标准的 NHP
吸入性炭疽研究和 I 期临床研究,所有这些都支持 FDA 批准治疗
动物规则下的炭疽病。
英文摘要
ABSTRACT
The goal of this project is to continue developing teixobactin (TXB) as an antibiotic to
combat weaponized anthrax. This work will be done in parallel to an ongoing preclinical
development program, which is advancing TXB for treating infections caused by other serious
pathogens such as methicillin resistant Staphylococcus aureus (MRSA). TXB has shown
excellent efficacy in several animal models of infection, including a rabbit model of inhalation
anthrax recently run at the University of Texas Medical Branch (Galveston, TX). Due to TXB’s
unusual mechanism of action – binding two different bacterial cell wall targets, neither of which is
a protein – TXB represents an example of a compound that is exceptionally free of resistance
development and thus is an excellent candidate as a countermeasure for anthrax.
The work in this grant will include the following Specific Aims: Aim 1 will provide at least
50 grams of non-cGMP teixobactin to fulfill all studies in the proposal. In addition, at least 200
grams of cGMP material will be produced at a contract manufacturer for planned future studies.
Aim 2 will focus on the following studies to further understand TXB’s in vitro properties: (a) MIC
testing against a panel of key B. anthracis isolates, including isolates resistant to current anthrax
drugs; (b) determine B. anthracis resistance frequency to teixobactin; and (c) protein binding
studies using rabbit, nonhuman primate (NHP), and human serum to determine free drug levels.
Aim 3 will determine the minimal therapeutic TXB dose in the rabbit anthrax efficacy model, with
associated pharmacokinetic (PK) profiling and histopathology. The information in Aim 3, in
addition to the toxicology, safety and PK/PD studies being run in parallel with this project, will help
inform NHP and human dosing.
At the conclusion of this grant, TXB will be prepared to enter a GLP-compliant, NHP
inhalation anthrax study and a Phase I clinical study, all in support of FDA approval for treating
anthrax under the Animal Rule.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Teixobactin Development for Tuberculosis
-
批准号:10546221
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2022
-
负责人:Dallas Hughes
-
依托单位:
Developing Teixobactin for Respiratory Infections
-
批准号:10378726
-
项目类别:
-
资助金额:$119.51万
-
财政年份:2021
-
负责人:Dallas Hughes
-
依托单位:
Developing Teixobactin for Respiratory Infections
-
批准号:10201364
-
项目类别:
-
资助金额:$146.95万
-
财政年份:2021
-
负责人:Dallas Hughes
-
依托单位:
Developing Teixobactin for Respiratory Infections
-
批准号:10552672
-
项目类别:
-
资助金额:$114.8万
-
财政年份:2021
-
负责人:Dallas Hughes
-
依托单位:
Teixobactin Development for Anthrax
-
批准号:10192649
-
项目类别:
-
资助金额:$99.64万
-
财政年份:2020
-
负责人:Dallas Hughes
-
依托单位:
Teixobactin Development for Anthrax
-
批准号:10436153
-
项目类别:
-
资助金额:$99.28万
-
财政年份:2020
-
负责人:Dallas Hughes
-
依托单位:
Exploratory Chemistry on a new antibiotic
-
批准号:9294978
-
项目类别:
-
资助金额:$73.84万
-
财政年份:2016
-
负责人:Dallas Hughes
-
依托单位:
Preclinical development of teixobactin, a new antibiotic
-
批准号:8903692
-
项目类别:
-
资助金额:$74.97万
-
财政年份:2015
-
负责人:Dallas Hughes
-
依托单位:
Preclinical development of teixobactin, a new antibiotic
-
批准号:9000621
-
项目类别:
-
资助金额:$74.09万
-
财政年份:2015
-
负责人:Dallas Hughes
-
依托单位:
Selective agents against C. difficile infection
-
批准号:8842587
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2014
-
负责人:Dallas Hughes
-
依托单位:
Selective agents against C. difficile infection
-
批准号:8713336
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2014
-
负责人:Dallas Hughes
-
依托单位:
海外基金